The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

[1]  B. Davis,et al.  Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial , 2006, Circulation.

[2]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[3]  H. Yki-Järvinen.  The PROactive study: some answers, many questions , 2005, The Lancet.

[4]  J. Staessen,et al.  Evidence that new antihypertensives are superior to older drugs , 2005, The Lancet.

[5]  Barry R Davis,et al.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. , 2005, JAMA.

[6]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[7]  Thomas Lumley,et al.  Survival associated with two sets of diagnostic criteria for congestive heart failure. , 2004, American journal of epidemiology.

[8]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.

[9]  D. Neely.  ALLHAT, or the Soft Science of the Secondary End Point , 2004, Annals of Internal Medicine.

[10]  B. Davis,et al.  ALLHAT: Setting the Record Straight , 2004, Annals of Internal Medicine.

[11]  M. Domanski,et al.  Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. , 2004, Journal of cardiac failure.

[12]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[13]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[14]  L. Wilkins.  Diuretic Versus &agr;-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2003 .

[15]  D. Sica,et al.  A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, Current hypertension reports.

[16]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents , 2003 .

[17]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[18]  J. Cutler.  The ANBP2 and ALLHAT: Conflicting or Consistent? , 2003, Journal of clinical hypertension.

[19]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[20]  C. E. Machado,et al.  Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 1998, Hypertension.

[21]  Michael A. Weber,et al.  The ALLHAT Report: A Case of Information and Misinformation , 2003, Journal of clinical hypertension.

[22]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[23]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[24]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[25]  B. Davis,et al.  P-444: Validation of heart failure events in ALLHAT participants assigned to doxazosin , 2001 .

[26]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[27]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[28]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[29]  M. Blaufox,et al.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. , 1997, JAMA.

[30]  B. Massie,et al.  Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.

[31]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[32]  B R Davis,et al.  Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. , 1996, American journal of hypertension.

[33]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[34]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.